X

Trial Profile

A Study to Assess the Safety, Tolerability, and Pharmacodynamics of MK-8931/SCH 900931 in Patients With Alzheimer's Disease [Phase 1b; Protocol No. 010-00 (Also Known as P07820)].

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 11 May 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Verubecestat (Primary)
Indications Alzheimer's disease
Focus Pharmacodynamics
Sponsors Merck Sharp & Dohme Corp.

Most Recent Events

02 Nov 2016 According to Merck & Co media release, reults were published online in Science Translational Medicine journal.
02 Nov 2016 Results published in the Merck & Co Media Release.
14 Jul 2013 Results presented at the Alzheimer's Association International Conference (AAIC), according to a media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com